Very early researchWithdrawnNCT04220892What this trial is testingPilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade GliomaWho this might be right forHigh Grade Glioma Jose Carrillo
Early research (Phase 1)Study completedNCT06267963What this trial is testingUnderstand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy AdultsWho this might be right forHealthy Participants Pfizer 12
Not applicableStudy completedNCT04133207What this trial is testingClinical Outcome and Toxicity Data in Patients With Advanced Breast Cancer Treated With CDK Inhibitors Combined With Endocrine TherapyWho this might be right forBreast Cancer Stage IV Hellenic Cooperative Oncology Group 340
Large-scale testing (Phase 3)Not Yet RecruitingNCT06996093What this trial is testingChemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 InhibitorWho this might be right forBreast Cancer Fudan University 2,508
Testing effectiveness (Phase 2)Active Not RecruitingNCT01723774What this trial is testingPD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast CancerWho this might be right forBreast Neoplasms Washington University School of Medicine 84
Early research (Phase 1)Study completedNCT02499146What this trial is testingPalbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast CancerWho this might be right forAdvanced Breast Cancer Pfizer 26
Testing effectiveness (Phase 2)Ended earlyNCT04863248What this trial is testingTrilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)Who this might be right forMetastatic Non-Small Cell Lung CancerNSCLCLung Cancer G1 Therapeutics, Inc. 10
Large-scale testing (Phase 3)Study completedNCT04799249What this trial is testingTrilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)Who this might be right forTNBC - Triple-Negative Breast CancerBreast Cancer G1 Therapeutics, Inc. 194
Large-scale testing (Phase 3)Looking for participantsNCT06044623What this trial is testingImplementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer PatientsWho this might be right forMetastatic Breast CancerAdvanced Breast CancerQuality of Life+2 more Region Örebro County 495
Testing effectiveness (Phase 2)Study completedNCT02441946What this trial is testingA Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast CancerWho this might be right forBreast CancerHormone Receptor Positive TumorEarly-Stage Breast Carcinoma Eli Lilly and Company 224
Not applicableUnknownNCT05051956What this trial is testingEvaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients?Who this might be right forCan the Geriatric Questionnaires Predict Adverse Effects in Geriatric Breast Cancer Patients Treated With Cyclin-dependent Kinase 4 and 6 Inhibitors Namik Kemal University 140
Not applicableStudy completedNCT07498413What this trial is testingEpidemiology and Treatment of HR+/HER2- Breast Cancer in EnglandWho this might be right forBreast Cancer Novartis Pharmaceuticals 218,677
Testing effectiveness (Phase 2)Study completedNCT02530320What this trial is testingSafety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB PreservedWho this might be right forOligodendrogliomaOligoastrocytoma Grupo Español de Investigación en Neurooncología 34
Not applicableStudy completedNCT06367335What this trial is testingCharacteristics and Predictors of Liver Injury in Cyclin-dependent Kinase Inhibitors 4/6 (CDK4/6)-Treated Patients With Advanced Breast CancerWho this might be right forDILI University of Milano Bicocca 128
Early research (Phase 1)Study completedNCT05923411What this trial is testingMultiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy AdultsWho this might be right forHealthy Participants Pfizer 113
Early research (Phase 1)Study completedNCT04124653What this trial is testingEvaluate the Safety, Tolerability, and Pharmacokinetics of PF-06842874 in Healthy ParticipantsWho this might be right forHealthy Participants Pfizer 44
Testing effectiveness (Phase 2)Looking for participantsNCT06947811What this trial is testingAlmonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS MutationsWho this might be right forEGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor Sun Yat-sen University 71
Not applicableStudy completedNCT05361655What this trial is testingReal-World Effectiveness of Palbociclib in Combination With an Aromatase InhibitorWho this might be right forMetastatic Breast Cancer Pfizer 2,888
Early research (Phase 1)Study completedNCT01188252What this trial is testingClinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced MalignanciesWho this might be right forNeoplasms Bayer 112
Testing effectiveness (Phase 2)Study completedNCT01291017What this trial is testingCyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.Who this might be right forNon-small Cell Lung Cancer University of Florida 19